COVID-19 VACCINE:

Dpx-Covid-19 Peptide antigens

researcher:

IMV + Dalhousie University + Izaak Walton Killam Health Center + Nova Scotia Health Authority + Canadian Immunization Research Network + University of Laval + Global Urgent and Advanced Research and Development in Canada

https://imv-inc.com/

(Canada)

vaccine type: Protein subunit

Distribution updates

currently no distribution info

Human Testing updates (clinical trials)

PHASE 1

in definition (expecting to start Q3 2020)

with 48 people

Oct 08	DPX-COVID-19 has the potential to improve the duration of the immune response and protect older adults and more vulnerable individuals (by imv-inc.com)
May 15	IMV's vaccine current advance will allow it to enter into clinical trials later this summer (by businesswire.com)
Mar 30	IMV is planning to test its vaccine on 48 people in Nova Scotia and Quebec this summer (by imv-inc.com)

Animal Testing updates (pre-clinical trials)

start date: April 2020

May 21	IMV's vaccine advance into human clinical studies due to showing positive preclinical results (by biospace.com)
May 21	IMV announced positive preclinical results showing robust immunogenic and antibody responses (by businesswire.com)
Apr 15	IMV will start testing on animals in April to validate safety and potency before human trials (by seekingalpha.com)

early development updates

Jul 14

IMV is working closely with regulatory agencies to initiate clinical studies as quick as possible (by businesswire.com)

funding:

Canadian government agencies CA$4.75 million

Aug 05

Canadian govt will contribute up to CA$4.75m to advance Phase 1 clinical trials of IMV's vaccine (by imv-inc.com)

partnerships:

Mar 18

IMV announced the development of a vaccine in collaboration with multiple partners (by imv-inc.com)